Carolina Pinzon Escobar, MD
Critical Care Medicine · Jersey City, NJNPI 1942633656
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.2% — the pattern of someone who eats at a lot of different presentations.
Across 101 payments — averaging $27.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$540
- AstraZeneca$486
- Shionogi Inc$478
- AbbVie$196
- Mallinckrodt Hospital Products Inc.$150
- Gilead$122
- plus $846 from 21 others
What the payments were for
- Food & beverage$2,73997%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 41 | $540 |
| AstraZeneca | 13 | $486 |
| Shionogi Inc | 4 | $478 |
| AbbVie(2 entities) | 6 | $196 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| Gilead | 1 | $122 |
| CSL Behring | 1 | $110 |
| Johnson & Johnson | 1 | $81 |
| Chiesi USA, Inc. | 1 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Sanofi | 5 | $80 |
| Boehringer Ingelheim | 4 | $64 |
| Mylan Specialty L.p. | 4 | $62 |
| Regeneron Healthcare Solutions, Inc. | 4 | $58 |
| Insmed, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $27 |
| Boston Scientific | 1 | $23 |
| Incyte Corporation | 1 | $19 |
| Resmed Corp | 1 | $18 |
| Merck | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Octapharma USA, Inc. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Eisai Inc. | 1 | $12 |
| Akcea Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,819 in reported general payments places this provider in the 75th percentile of 254 critical care medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $139,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 115 | $103,455 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 75 | $42,450 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $22,476 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $8,690 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,718 |
| Spiriva RespimatTiotropium Bromide | 11 | $7,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 168 | $5,159 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,387 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $2,818 |
| Azelastine Hcl | 75 | $1,989 |
| Wixela InhubFluticasone Propion/Salmeterol | 19 | $1,955 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $1,721 |
| Montelukast Sodium | 42 | $628 |
| Fluticasone Propionate | 35 | $501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $540 | $177,071257 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $64 | $147,15422 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $486 | $12,10531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 254 critical care medicine providers in New Jersey.
Other critical care medicine in Jersey City
- Fariborz RezaiLivingston$2.3M
- Eric TellerHackensack$217K
- R Phillip DellingerCamden$74K
- Raghad SaidHackensack$48K
- Neha VagadiaMarlton$31K
- Mark RamzyWest Orange$31K
- Shawana HussainCamden$19K
- Theodore PlushCamden$18K
- Martin LansangFlemington$18K
- Stephen TrzeciakCamden$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.